ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HROW vs CTY // RSI-14 & 200D SMA MOMENTUM

Harrow Inc. (NASDAQ) VS. City Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: HROW 1 — CTY 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: CTY
rsi-technicals
38.5
rsi-technicals
61.6
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HROW VS. CTY) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HROW CTY SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 75.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 42.90% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation 33.6x — — TIE /valuation <GO>
Free Cash Flow Yield 3.82% — — TIE /fcf-yield <GO>
Operating Margin 11.20% — — TIE /operating-margins <GO>
Net Profit Margin -1.90% — — TIE /net-margins <GO>
Revenue Growth (YoY) 36.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.67 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 — — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 38.5 61.6 -23.06 CTY /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.12B $1.11B $9.9M HROW /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HROW REV CTY REV HROW GROSS % CTY GROSS % HROW FCF CTY FCF
FY 2025 $272.3M — 75.1% — $43.0M —
FY 2024 $199.6M — 75.3% — -$23.8M —
FY 2023 $130.2M — — — $3.8M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HROW // BETA —
CTY // BETA —